Arbutus Biopharma Makes Headway in Hepatitis B Treatment and Defends Intellectual Property Amidst Q1 2024 Financial Release
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS) has unveiled its growth during the first quarter of 2024, particularly in the development of its Hepatitis B virus (HBV) therapeutic resources. …
Arbutus Biopharma Makes Headway in Hepatitis B Treatment and Defends Intellectual Property Amidst Q1 2024 Financial Release Read More